Event Recordings
Day 1 | Day 2
Day 1 Welcome
Joseph Wu, MD, PhD
Director, Stanford Cardiovascular Institute; Simon H. Stertzer, MD, Professor of Medicine and Radiology, Stanford University
Marc Tessier-Lavigne, PhD
President, Stanford University
Lloyd Minor, MD
Dean, Stanford School of Medicine
Session I: Biology of Disease
Moderators: Helen Blau, PhD, and Mark Mercola, PhD
New Paradigms in Drug Discovery
Roger Kornberg, PhD, Mrs. George A. Winzer Professor in Medicine, Stanford University; Nobel prize in 2006
Toward a Single-dose, Room-temperature Stable COVID-19 Vaccine
Peter Kim, PhD, Virginia and D.K. Ludwig Professor of Biochemistry, Stanford University
Session II: Investing in Discovery
Moderators: Nina Kjellson and Kuldev Singh, MD
Voice of the Body: The Data Journey
Young Sohn, MS, Chairman of the Board, HARMAN and Senior Advisor, Samsung Electronics
Breaking Through Impossible
Jürgen Eckhardt, MD, Head of Leaps by Bayer
Venture and Growth Technology and Healthcare at Scale
Carmen Chang, MA, JD, General Partner; Head of Asia, New Enterprise Associates
Venture Investment in Drug Discovery – A European Perspective
Nanna Lüneborg, PhD, MBA, Partner, Novo Ventures
Panel Discussion
Moderators: Nina Kjellson and Kuldev Singh, MD
Featuring:
Jürgen Eckhardt, MD
Head of Leaps by Bayer
Young Sohn, MS
Chairman of the Board, HARMAN and Senior Advisor, Samsung Electronics
Carmen Chang, MA, JD
General Partner; Head of Asia, New Enterprise Associates
Nanna Lüneborg, PhD, MBA
Partner, Novo Ventures
Session III: Discovery Research I
Moderators: Sandra Horning, MD, and Sanjay Malhotra, PhD
Making Medicines – A Partnership
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing, Gilead
RNA Targeted Drug Discovery: From Pipe Dream to Reality
Stanley T. Crooke, MD, PhD, Ionis Pharmaceuticals Executive Chairman of the Board
Re-defining the Novo Nordisk Approach to Drug Discovery
Marcus Schindler, PhD, Executive Vice President and CSO of Research & Early Development, Novo Nordisk
Human Genetics, Functional Genomics and AI/ML in Drug Discovery
Hal Barron, MD, CSO and President, GlaxoSmithKline
Drug Discovery: Where are We Headed?
Wendy Young, PhD, Senior Vice President, Small Molecule Drug Discovery, Genentech
Panel Discussion
Moderators: Sandra Horning, MD, and Sanjay Malhotra, PhD
Featuring:
Taiyin Yang, PhD
Executive Vice President, Pharmaceutical Development and Manufacturing, Gilead
Stanley T. Crooke, MD, PhD
Ionis Pharmaceuticals Executive Chairman of the Board
Marcus Schindler, PhD
Executive Vice President and CSO of Research & Early Development, Novo Nordisk
Hal Barron, MD
CSO and President, GlaxoSmithKline
Wendy Young, PhD
Senior Vice President, Small Molecule Drug Discovery, Genentech
Session IV: Disseminating Drug Discovery Findings
Moderators: Amanda Chase, PhD, and Mark Mercola, PhD
Panel Discussion
Featuring:
Michael Basson, PhD
Senior Editor, Nature Medicine
Orla Smith, PhD
Editor, Science Translational Medicine
Michael Nedelman
CNN Producer
Session V: Presentation of Lifetime Achievement Awards
Moderator: Philip Pizzo, MD
Presentation of Lifetime Achievement Awards
Philip Pizzo, MD, David and Susan Heckerman Professor and Professor of Microbiology and Immunology, Stanford University
Virus-like Particle Vaccination for Preventing HPV-Associated Cancers
Douglas R. Lowy, MD, Principal Deputy Director, National Cancer Institute
Moving Beyond Personalized Therapies for Cancer
John T. Schiller, PhD, Deputy Chief, Laboratory of Cellular Oncology
Q&A Session
Featuring:
Douglas R. Lowy, MD
Principal Deputy Director, National Cancer Institute
John T. Schiller, PhD
Deputy Chief, Laboratory of Cellular Oncology
Mathai Mammen, MD, PhD
Global Head of Research and Development, Janssen
Yvonne Maldonado, MD
Sr Associate Dean, Faculty Development and Diversity, Taube Professor of Global Health and Infectious Diseases
Day 1 Closing Remarks
Joseph Wu, MD, PhD, Director, Stanford Cardiovascular Institute, Simon H. Stertzer, MD, Professor of Medicine and Radiology, Stanford University